Drug Search Results
More Filters [+]

ATR-258

Alternative Names: ATR-258, ATR 258, ATR258
Latest Update: 2024-07-01
Latest Update Note: Clinical Trial Update

Product Description

Studies in type 2 diabetic animal models have demonstrated that Atrogi’s lead drug candidate ATR-258 lowers blood glucose to healthy levels independent of insulin. In addition, the drug candidate enhances insulin sensitivity and lowers insulin production. The treatment can potentially function as a stand-alone or a combination therapy. (Sourced from: https://atrogi.com/our-solution/)

Mechanisms of Action: ADRB2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Atrogi AB
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ATR-258

Countries in Clinic: Germany, Sweden

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: General Diabetes|Healthy Volunteers|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Attractive 2

P1

Completed

Healthy Volunteers|General Diabetes

2024-05-27

ATR-258-study-1

P1

Completed

Type 2 Diabetes

2023-10-04

Recent News Events

Date

Type

Title